Phase 1b/2 trial of Orca-T in patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, myelofibrosis and other hematological malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orca-T (Primary)
Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

01 Oct 2022 Results reporting safety and efficacy of Orca-T in patients with hematologic malignancies who received Orca-T in a single-center Phase 1/2 study (NCT01660607) and a multicenter Phase 1b study (NCT04013685) published in the Clinical Lymphoma, Myeloma & Leukemia
17 Dec 2021 New trial record
11 Dec 2021 According to an Orca Bio media release, positive pooled results from single-center Phase 2 and multi-center Phase 1b trials from 109 patients were presented at the 63rd American Society of Hematology (ASH) Annual Meeting 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com